• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abeona Therapeutics Inc. - Common Stock (NQ:ABEO)

5.030 +0.020 (+0.40%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,213,610
Open 5.090
Bid (Size) 5.050 (100)
Ask (Size) 5.090 (800)
Prev. Close 5.010
Today's Range 4.985 - 5.105
52wk Range 4.000 - 7.650
Shares Outstanding 54,191,361
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 29, 2026
From Pomerantz LLP
Via GlobeNewswire

Performance

52-Week Range 34.2% below 52-week high
5.030
4.0052W Low 7.6552W High
1 Week 6.9% below 1-week high
4.991W Low 5.401W High

Abeona Therapeutics Inc. - Common Stock (ABEO) traded between $4.00 and $7.65 over the past 52 weeks and last traded at $5.03, 34.2% below its 52-week high. Over the past week it ranged between $4.99 and $5.40.

Past 12 Months
-4.9%
-15.2%
-20.3%
+5.7%
-5.3%
-7.0%
1W -$0.26
1M -$0.90
3M -$1.28
6M +$0.27
YTD -$0.28
1Y -$0.38

ABEO was -7.0% over the past year, +5.7% over six months, -5.3% year to date, -4.9% in the last week.

12 Months vs Market
ABEO
-7.0%
DIA
+9.3%
SPY
+15.0%
QQQ
+24.3%
IWM
+14.5%

Over the past 12 months ABEO returned -7.0% versus DIA (Dow) +9.3%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +14.5%.

Volume & Liquidity 0.85× 3-mo avg
Today 1,213,610 3-mo avg 1.4M
1W
1.2M
1M
1.5M
3M
1.4M
6M
1.3M
YTD
1.3M
1Y
1.4M

ABEO most recently traded 1,213,610 shares against a 3-month average daily volume of 1.4M.

More News

Read More
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 22, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics Highlights ZEVASKYN Launch Momentum, Revenue Growth at H.C. Wainwright ↗
September 22, 2026
Via MarketBeat
News headline image
Abeona Expands ZEVASKYN Network as RDEB Launch Gains Momentum ↗
September 22, 2026
Via MarketBeat
News headline image
Abeona Therapeutics® Congratulates Ultragenyx on U.S. FDA Approval of FAYUVI™ Gene Therapy for Sanfilippo Syndrome Type A (MPS IIIA)
September 18, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
September 16, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 15, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law
September 08, 2026
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 08, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
September 02, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO
September 01, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 01, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona (ABEO) Q2 2026 Earnings Call Transcript ↗
August 20, 2026
Via The Motley Fool
Topics Earnings
News headline image
Abeona Therapeutics Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via Benzinga
Topics Earnings
News headline image
Abeona Therapeutics Q2 Earnings Call Highlights ↗
August 13, 2026
Via MarketBeat
Topics Earnings
News headline image
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
August 13, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
August 06, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
August 04, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
July 21, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 01, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
May 26, 2026
From Abeona Therapeutics Inc.
Via GlobeNewswire
News headline image
Abeona (ABEO) Q1 2026 Earnings Transcript ↗
May 13, 2026
Via The Motley Fool

Frequently Asked Questions

Is Abeona Therapeutics Inc. - Common Stock publicly traded?
Yes, Abeona Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Abeona Therapeutics Inc. - Common Stock trade on?
Abeona Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Abeona Therapeutics Inc. - Common Stock?
The ticker symbol for Abeona Therapeutics Inc. - Common Stock is ABEO on the Nasdaq Stock Market
What is the current price of Abeona Therapeutics Inc. - Common Stock?
The current price of Abeona Therapeutics Inc. - Common Stock is 5.030
When was Abeona Therapeutics Inc. - Common Stock last traded?
The last trade of Abeona Therapeutics Inc. - Common Stock was at 10/02/26 04:00 PM ET
What is the market capitalization of Abeona Therapeutics Inc. - Common Stock?
The market capitalization of Abeona Therapeutics Inc. - Common Stock is 272.58M
How many shares of Abeona Therapeutics Inc. - Common Stock are outstanding?
Abeona Therapeutics Inc. - Common Stock has 273M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap